Internal Medicine, Medical Oncology · Durham, NC
NPI
1790997989
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
40 Duke Medicine Cir
Durham, NC, 27710
Phone (919) 684-8111
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
410 services
Medicare patients, 2024
85
Average age 74
Drug cost, 2024
$3.0M
377 prescriptions
Company payments, 2025
$464K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas W Leblanc was code 99233 (hospital e&m - subsequent), 180 times for 35 patients. In total Thomas W Leblanc billed 410 services in 11 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-06-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 180 | 35 | $88.16 | $16K |
| 99215 Office E&M - Established | Office | 96 | 45 | $97.35 | $9,346 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 90 | 42 | $11.90 | $1,071 |
| 99223 Hospital E&M - Initial | Facility | 12 | 11 | $124.06 | $1,489 |
| 99239 Hospital Discharge Management | Facility | 11 | 11 | $84.79 | $933 |
By year: 2022 $31K for 337 services; 2023 $24K for 254 services; 2024 $30K for 410 services.
Medicare prescription drug claims, 2024
In 2024, the drug Thomas W Leblanc prescribed most often to Medicare patients was Venclexta (Venetoclax), with 41 prescriptions and refills. In total Thomas W Leblanc wrote 377 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Venclexta Venetoclax | 41 | 41 | 12 | $191K |
| Cresemba Isavuconazonium Sulfate | 26 | 26 | Under 11 | $153K |
| Acyclovir Generic | 25 | 31 | Under 11 | $182 |
| Promacta Eltrombopag Olamine | 22 | 22 | Under 11 | $448K |
| Allopurinol Generic | 20 | 24 | Under 11 | $138 |
| Levofloxacin Generic | 20 | 20 | Under 11 | $202 |
| Iclusig Ponatinib Hcl | 19 | 19 | Under 11 | $319K |
| Gabapentin Generic | 17 | 23 | Under 11 | $339 |
| Tasigna Nilotinib Hcl | 15 | 15 | Under 11 | $80K |
| Vanflyta Quizartinib Dihydrochloride | 13 | 13 | Under 11 | $296K |
| Tibsovo Ivosidenib | 12 | 12 | Under 11 | $274K |
| Ondansetron Hcl Generic | 11 | 11 | Under 11 | $37.41 |
| Ojjaara Momelotinib Dihydrochloride | 11 | 11 | Under 11 | $281K |
| Jakafi Ruxolitinib Phosphate | 11 | 11 | Under 11 | $163K |
Brand drugs: 223 claims; generic drugs: 154 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas W Leblanc $464K ($459K in general payments such as food, travel and fees and $4,288 for research) from 19 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $108K.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 58 | $108K |
| Abbvie Inc. ABBV | 58 | $74K |
| Incyte Corporation INCY | 70 | $72K |
| Stemline Therapeutics Inc. | 47 | $52K |
| Servier Pharmaceuticals LLC | 33 | $44K |
| Geron Corporation GERN | 15 | $23K |
| Rigel Pharmaceuticals, Inc. RIGL | 12 | $17K |
| Daiichi Sankyo Inc. 4568.T | 11 | $16K |
| Syndax Pharmaceuticals, Inc. SNDX | 12 | $12K |
| Astellas Pharma US Inc 4503.T | 9 | $12K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.